{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T12:06:27Z","timestamp":1789387587017,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T00:00:00Z","timestamp":1570752000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T00:00:00Z","timestamp":1570752000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1245\/s10434-019-07915-6","type":"journal-article","created":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T15:02:58Z","timestamp":1570806178000},"page":"4381-4389","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Heterogeneous Responses of Axillary Lymph Node Metastases to Neoadjuvant Chemotherapy are Common and Depend on Breast Cancer Subtype"],"prefix":"10.1245","volume":"26","author":[{"given":"Antonia","family":"Glaeser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Sinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Garcia-Etienne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Riedel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Hug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Schaefgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Golatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Hennigs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Feisst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christof","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4684-9099","authenticated-orcid":false,"given":"Joerg","family":"Heil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,11]]},"reference":[{"issue":"12","key":"7915_CR1","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1002\/cncr.25152","volume":"116","author":"LS Dominici","year":"2010","unstructured":"Dominici LS, Negron Gonzalez VM, Buzdar AU, Lucci A, Mittendorf EA, Le-Petross HT, et al. Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer. Cancer. 2010;116(12):2884\u20139.","journal-title":"Cancer"},{"issue":"52","key":"7915_CR2","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1002\/1097-0142(19831101)52:9<1551::AID-CNCR2820520902>3.0.CO;2-3","volume":"1983","author":"B Fisher","year":"1983","unstructured":"Fisher B, Bauer M, Wickerham D, Redmond C, Fisher E. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer: an NSABP update. Cancer. 1983. 1983;52:1551\u20137.","journal-title":"Cancer"},{"issue":"32","key":"7915_CR3","doi-asserted-by":"publisher","first-page":"3960","DOI":"10.1200\/JCO.2011.40.8369","volume":"30","author":"E Mamounas","year":"2012","unstructured":"Mamounas E, Anderson S, Dignam J, Bear H, Julian T, Geyer C Jr, et al. Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. J Clin Oncol. 2012;30(32):3960\u20136.","journal-title":"J Clin Oncol"},{"issue":"36","key":"7915_CR4","doi-asserted-by":"publisher","first-page":"9304","DOI":"10.1200\/JCO.2005.02.5023","volume":"23","author":"BT Hennessy","year":"2005","unstructured":"Hennessy BT, Hortobagyi GN, Rouzier R, Kuerer H, Sneige N, Buzdar AU, et al. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol. 2005;23(36):9304\u201311.","journal-title":"J Clin Oncol"},{"issue":"5","key":"7915_CR5","first-page":"732","volume":"237","author":"S Beenken","year":"2003","unstructured":"Beenken S, Urist M, Zhang Y, Desmond R, Krontiras H, Medina H, et al. Axillary lymph node status, but not tumor size, predicts locoregional recurrence and overall survival after mastectomy for breast cancer. Ann Surg. 2003;237(5):732\u20138.","journal-title":"Ann Surg"},{"issue":"24","key":"7915_CR6","doi-asserted-by":"publisher","first-page":"3657","DOI":"10.1200\/JCO.2006.07.4062","volume":"25","author":"A Lucci","year":"2007","unstructured":"Lucci A, McCall LM, Beitsch PD, Whitworth PW, Reintgen DS, Blumencranz PW, et al. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol. 2007;25(24):3657\u201363.","journal-title":"J Clin Oncol"},{"issue":"14","key":"7915_CR7","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1001\/jama.2013.278932","volume":"310","author":"JC Boughey","year":"2013","unstructured":"Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310(14):1455\u201361.","journal-title":"JAMA"},{"issue":"12","key":"7915_CR8","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/S1470-2045(14)70460-7","volume":"15","author":"M Donker","year":"2014","unstructured":"Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJH, Mansel RE, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15(12):1303\u201310.","journal-title":"Lancet Oncol"},{"issue":"6","key":"7915_CR9","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1001\/jama.2011.90","volume":"305","author":"AE Giuliano","year":"2011","unstructured":"Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305(6):569\u201375.","journal-title":"JAMA"},{"issue":"10","key":"7915_CR10","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1177\/000313489906501021","volume":"65","author":"JT Kakuda","year":"1999","unstructured":"Kakuda JT, Stuntz M, Trivedi V, Klein SR, Vargas HI. Objective assessment of axillary morbidity in breast cancer treatment. Am Surg. 1999;65(10):995\u20138.","journal-title":"Am Surg"},{"issue":"7","key":"7915_CR11","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S1470-2045(13)70166-9","volume":"14","author":"T Kuehn","year":"2013","unstructured":"Kuehn T, Bauerfeind I, Fehm T, Fleige B, Hausschild M, Helms G, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14(7):609\u201318.","journal-title":"Lancet Oncol"},{"issue":"6","key":"7915_CR12","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/jso.21128","volume":"98","author":"MZ Papa","year":"2008","unstructured":"Papa MZ, Zippel D, Kaufman B, Shimon-Paluch S, Yosepovich A, Oberman B, et al. Timing of sentinel lymph node biopsy in patients receiving neoadjuvant chemotherapy for breast cancer. J Surg Oncol. 2008;98(6):403\u20136.","journal-title":"J Surg Oncol"},{"issue":"10","key":"7915_CR13","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1200\/JCO.2015.64.0094","volume":"34","author":"AS Caudle","year":"2016","unstructured":"Caudle AS, Yang WT, Krishnamurthy S, Mittendorf EA, Black DM, Gilcrease MZ, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol. 2016;34(10):1072\u20138.","journal-title":"J Clin Oncol"},{"issue":"2","key":"7915_CR14","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1097\/SLA.0000000000000558","volume":"261","author":"M Donker","year":"2015","unstructured":"Donker M, Straver ME, Wesseling J, Loo CE, Schot M, Drukker CA, et al. Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure. Ann Surg. 2015;261(2):378\u201382.","journal-title":"Ann Surg"},{"issue":"2","key":"7915_CR15","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1159\/000127509","volume":"3","author":"A Wockel","year":"2008","unstructured":"Wockel A, Kreienberg R. First revision of the german s3 guideline \u2018diagnosis, therapy, and follow-up of breast cancer. Breast Care. 2008;3(2):82\u20136.","journal-title":"Breast Care"},{"issue":"2","key":"7915_CR16","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1159\/000475698","volume":"12","author":"M Gnant","year":"2017","unstructured":"Gnant M, Harbeck N, Thomssen C. St. Gallen\/Vienna 2017: a brief summary of the consensus discussion about escalation and de-escalation of primary breast cancer treatment. Breast Care. 2017;12(2):102\u20137.","journal-title":"Breast Care"},{"issue":"11","key":"7915_CR17","doi-asserted-by":"publisher","first-page":"3475","DOI":"10.1245\/s10434-016-5463-1","volume":"23","author":"AV Barrio","year":"2016","unstructured":"Barrio AV, Mamtani A, Edelweiss M, Eaton A, Stempel M, Murray MP, et al. How often is treatment effect identified in axillary nodes with a pathologic complete response after neoadjuvant chemotherapy? Ann Surg Oncol. 2016;23(11):3475\u201380.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"7915_CR18","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1159\/000446941","volume":"11","author":"C Liedtke","year":"2016","unstructured":"Liedtke C, Thill M, Committee AGOB. AGO recommendations for the diagnosis and treatment of patients with early breast cancer: update 2016. Breast Care. 2016;11(3):204\u201314.","journal-title":"Breast Care"},{"issue":"3","key":"7915_CR19","first-page":"297","volume":"180","author":"DM Sataloff","year":"1995","unstructured":"Sataloff DM, Mason BA, Prestipino AJ, Seinige UL, Lieber CP, Baloch Z. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg. 1995;180(3):297\u2013306.","journal-title":"J Am Coll Surg"},{"issue":"9938","key":"7915_CR20","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164\u201372.","journal-title":"Lancet"},{"issue":"2","key":"7915_CR21","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1200\/JCO.1999.17.2.460","volume":"17","author":"HMNLA Kuerer","year":"1999","unstructured":"Kuerer HMNLA, Smith TL, Ames FC, Hunt KK, Dhingra K, Theriault RL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999;17(2):460\u20139.","journal-title":"J Clin Oncol"},{"issue":"18","key":"7915_CR22","doi-asserted-by":"publisher","first-page":"3342","DOI":"10.1016\/j.ejca.2012.05.023","volume":"48","author":"N Houssami","year":"2012","unstructured":"Houssami N, Macaskill P, von Minckwitz G, Marinovich ML, Mamounas E. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer. 2012;48(18):3342\u201354.","journal-title":"Eur J Cancer"},{"issue":"2","key":"7915_CR23","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/bjs5.6","volume":"1","author":"MR Boland","year":"2017","unstructured":"Boland MR, McVeigh TP, O\u2019Flaherty N, Gullo G, Keane M, Quinn CM, et al. Impact of receptor phenotype on nodal burden in patients with breast cancer who have undergone neoadjuvant chemotherapy. BJS Open. 2017;1(2):39\u201345.","journal-title":"BJS Open"},{"issue":"2","key":"7915_CR24","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1245\/s10434-017-6263-y","volume":"25","author":"Z Al-Hilli","year":"2018","unstructured":"Al-Hilli Z, Hoskin TL, Day CN, Habermann EB, Boughey JC. Impact of neoadjuvant chemotherapy on nodal disease and nodal surgery by tumor subtype. Ann Surg Oncol. 2018;25(2):482\u201393.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"7915_CR25","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/s12253-018-0557-7","volume":"25","author":"T Zombori","year":"2018","unstructured":"Zombori T, Cserni G. Patterns of regression in breast cancer after primary systemic treatment. Pathol Oncol Res. 2018;25(3):1153\u20131161.","journal-title":"Pathol Oncol Res"},{"key":"7915_CR26","doi-asserted-by":"publisher","first-page":"4324863","DOI":"10.1155\/2016\/4324863","volume":"2016","author":"DC McFarland","year":"2016","unstructured":"McFarland DC, Naikan J, Rozenblit M, Mandeli J, Bleiweiss I, Tiersten A. Changes in pathological complete response rates after neoadjuvant chemotherapy for breast carcinoma over five years. J Oncol. 2016;2016:4324863.","journal-title":"J Oncol"},{"issue":"1","key":"7915_CR27","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.clbc.2013.08.017","volume":"14","author":"TP McVeigh","year":"2014","unstructured":"McVeigh TP, Al-Azawi D, Kearney DE, Malone C, Sweeney KJ, Barry K, et al. Assessing the impact of neoadjuvant chemotherapy on the management of the breast and axilla in breast cancer. Clin Breast Cancer. 2014;14(1):20\u20135.","journal-title":"Clin Breast Cancer"},{"issue":"4","key":"7915_CR28","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.clbc.2016.02.009","volume":"16","author":"K Enokido","year":"2016","unstructured":"Enokido K, Watanabe C, Nakamura S, Ogiya A, Osako T, Akiyama F, et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with an initial diagnosis of cytology-proven lymph node-positive breast cancer. Clin Breast Cancer. 2016;16(4):299\u2013304.","journal-title":"Clin Breast Cancer"},{"issue":"9","key":"7915_CR29","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.1245\/s10434-018-6637-9","volume":"25","author":"TT Nguyen","year":"2018","unstructured":"Nguyen TT, Hoskin TL, Day CN, Degnim AC, Jakub JW, Hieken TJ, et al. Decreasing use of axillary dissection in node-positive breast cancer patients treated with neoadjuvant chemotherapy. Ann Surg Oncol. 2018;25(9):2596\u2013602.","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"7915_CR30","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1016\/j.ejca.2004.04.007","volume":"40","author":"MS Gaston","year":"2004","unstructured":"Gaston MS, Dixon JM. A survey of surgical management of the axilla in UK breast cancer patients. Eur J Cancer. 2004;40(11):1738\u201342.","journal-title":"Eur J Cancer"},{"issue":"1","key":"7915_CR31","doi-asserted-by":"publisher","first-page":"66","DOI":"10.4103\/0019-509X.98934","volume":"49","author":"KK Bassi","year":"2012","unstructured":"Bassi KK, Seenu V, Srivastava A, Al Sharara N. Role of axillary sampling in the era of sentinel lymph node biopsy: a critical review. Indian J Cancer. 2012;49(1):66\u201373.","journal-title":"Indian J Cancer"},{"issue":"6","key":"7915_CR32","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S0748-7983(03)00076-3","volume":"29","author":"FJ Hoar","year":"2003","unstructured":"Hoar FJ, Stonelake PS. A prospective study of the value of axillary node sampling in addition to sentinel lymph node biopsy in patients with breast cancer. Eur J Surg Oncol. 2003;29(6):526\u201331.","journal-title":"Eur J Surg Oncol"},{"key":"7915_CR33","unstructured":"Lumachi F, Norberto L, Zanella S, Marino F, Basso SM, Basso U, et al. Axillary node sampling in conjunction with sentinel node biopsy in patients with breast cancer. A prospective preliminary study. Anticancer Res. 2011;31(2):693\u20137."},{"issue":"5","key":"7915_CR34","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.2214\/AJR.05.0936","volume":"186","author":"S Alvarez","year":"2006","unstructured":"Alvarez S, Anorbe E, Alcorta P, Lopez F, Alonso I, Cortes J. Role of sonography in the diagnosis of axillary lymph node metastases in breast cancer: a systematic review. AJR Am J Roentgenol. 2006;186(5):1342\u20138.","journal-title":"AJR Am J Roentgenol"},{"issue":"5","key":"7915_CR35","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.clbc.2017.04.006","volume":"17","author":"TJA van Nijnatten","year":"2017","unstructured":"van Nijnatten TJA, Simons JM, Smidt ML, van der Pol CC, van Diest PJ, Jager A, et al. A novel less-invasive approach for axillary staging after neoadjuvant chemotherapy in patients with axillary node-positive breast cancer by combining radioactive iodine seed localization in the axilla with the Sentinel Node Procedure (RISAS): a Dutch Prospective Multicenter Validation Study. Clin Breast Cancer. 2017;17(5):399\u2013402.","journal-title":"Clin Breast Cancer"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-019-07915-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-019-07915-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-019-07915-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T11:10:01Z","timestamp":1695294601000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-019-07915-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,11]]},"references-count":35,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["7915"],"URL":"https:\/\/doi.org\/10.1245\/s10434-019-07915-6","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,11]]},"assertion":[{"value":"28 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}},{"value":"The study was approved by the ethics committee of the University of Heidelberg (reference number: S-241\/2017). All procedures performed in this study were in accordance with the 1964 Helsinki declaration and its later amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Standard"}}]}}